
MoonLake's Stock Plummets 89% Amid Autoimmune Drug Trial Failures
MoonLake Immunotherapeutics' stock plummeted over 88% after its skin disease treatment, sonelokimab, showed only mixed results in clinical trials for hidradenitis suppurativa, with only one of two studies meeting its goal and a higher-than-expected placebo response, leading to investor disappointment.
